1. Centre for Innovation in Regulatory Science. New drug approvals in ICH countries, 2005–2014: Focus on facilitated regulatory pathways and orphan designations. R&D Briefing 57. April 2015. http://www.cirsci.org/sites/default/files/CIRS_R&D_57_ICH_%20approval_%20times_2005-2014_%2006072015.pdf. Accessed October 20, 2015.
2. World Health Organization (WHO). The world health report. Health systems financing: the path to universal coverage. http://www.who.int/whr/2010/10_summary_en.pdf?ua=1. Accessed October 20, 2015.
3. European Federation of Pharmaceutical Industries and Associations (EFPIA). Patients’ W.A.I.T. indicator—Report 2011. http://www.efpia.eu/documents/33/64/Market-Access-Delays. Accessed October 20, 2015.
4. Cohen J., Faden L., Predaris S., Young B. Patient access to pharmaceuticals: an international comparison. Eur J Health Econ. 2007;8:253–266.
5. Cohen J., Cairns C., Paquette C., Faden L. Comparing patient access to pharmaceuticals in the UK and in the US. Appl Health Econ Health Policy. 2006;5:177–187.